Biohaven is a pharmaceutical company that researches and develops novel drugs for the treatment of neurological and neuropsychiatric diseases.Read more
Covis Pharma is seen as one of Biohaven's biggest rivals. Covis Pharma is headquartered in Baarn, Utrecht, and was founded in 2011. Like Biohaven, Covis Pharma also works within the Pharmaceuticals sector. Covis Pharma generates 30% the revenue of Biohaven.
Neuropore is seen as one of Biohaven's top competitors. Neuropore was founded in 2008, and its headquarters is in San Diego, California. Neuropore operates in the Biotechnology industry. Neuropore has 38 fewer employees than Biohaven.
October 26, 2021
October 26, 2021
Biohaven's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 1.3B. Over the last four quarters, Biohaven's revenue has grown by 426.1%. Specifically, in Q2 2021's revenue was $92.9M; in Q1 2021, it was $43.8M; in Q4 2020, it was $35.1M; in Q3 2020, Biohaven's revenue was $17.7M.
These are all the companies that Biohaven has acquired. Biohaven's latest acquisition was Kleo Pharmaceuticals, Inc. in Jan 2021. Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.
Since Biohaven was founded in 2013, it has participated in 3 rounds of funding. In total Biohaven has raised $748.3M. Biohaven's last funding round was on Aug 2020 for a total of $500.0M
These are all the companies that Biohaven has invested in. Biohaven's latest investment was Kleo in Aug 28,. Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.